Canagliflozin FDA Approved For Type 2 Diabetes


Canagliflozin FDA ApprovedCanagliflozin FDA approved as a new and unique treatment for type 2 diabetes.

There were nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed positive results with greater glycemic control in patients.

The recommended use for Canagliflozin patients includes a strict regimen of diet and exercise. The drug also outperforms similar diabetes drugs like Glimepiride (Amaryl) and Sitagliptin (Januvia).

However, the need for additional postmarketing studies is required by the FDA.

Some “Canagliflozin” Factoids:

  • Canagliflozin does not rely on patient’s insulin levels to succeed.
  • Canagliflozin is a unique inhibitor of sodium glucose co-transporter 2, as well as a potential treatment for type 2 diabetes.
  • Results from five Phase lll clinical trials, which were presented at the 72nd American Diabetes Association Annual Scientific Sessions on June 9, 2012.
  • Results in favor of Canagliflozin were positive, showing that a once daily 300 mg dose of this medication provided significantly greater reductions in A1C levels relative to comparators.
  • In January 2013 an FDA Advisory Committee recommended approval of Canagliflozin for type 2 diabetes in adults based on efficacy & safety results from the comprehensive clinical development program
  • Canagliflozin CAS# 842133-18-0 is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney
  • Canagliflozin will be marketed under the brand name INVOKANA™ by J&J

LGM Pharma provides Canagliflozin CAS# 842133-18-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:
One comment
  • Tom Hanks Diabetes - A Type 2 Diabetes Diagnosis - LGM Pharma Blog
    Posted on October 17, 2013 at 6:40 am

    […] is a Best Selling Pharmaceutical Product article) and the once daily Canagliflozin (check out The FDA Approves Canagliflozin For Type 2 Diabetes). Further research and development is needed to combat this ballooning problem not only in the […]

Comments are closed.